Lexicon earnings beat by $0.03, revenue topped estimates

Lexicon Pharmaceuticals (LXRX) reported Q3 EPS of -$0.03, beating estimates by $0.03, with revenue of $11.25M, surpassing expectations of $2.83M. The stock is down 40.08% over 3 months but up 3.5% year-over-year. InvestingPro rates its financial health as 'good performance'.

Original reporting
Published Nov 5, 2026, 12:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LXRX
Bullish
medium confidence
Mentioned
$LXRX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LXRXBullishMed
01

Why it matters

The earnings beat provides a fresh data point for traders, but the small scale limits market impact.

02

Market read

Earnings surprise for a low‑cap biotech; modest trading opportunity.

03

What to watch

Potential upcoming regulatory milestones or pipeline news could drive future moves beyond the earnings beat.

Relevance 6/10Novelty 6/10Timing: after-hours reaction

Background

Lexicon (NASDAQ: LXRX) is a micro‑cap biotech that recently posted a Q3 earnings surprise.

Company-level read

Ticker impact

$LXRXBullishMedium confidence
Context

Lexicon reported Q3 EPS of -$0.03 beating the -$0.06 estimate and revenue of $11.25M versus $2.83M consensus.

Expected impact

modest upside as investors price in the earnings beat

Evidence & confidence

The surprise beat is material for LXRX but the absolute dollar amounts are small, limiting the move.

Market effects

Limited impact on the broader biotech sector; micro‑cap earnings beats are often isolated.

Primarily U.S. over‑the‑counter market; no broader regional effect.

Low global relevance due to the company's small size.

Counterpoint

The beat may be priced in quickly, leading to a short‑term pullback.

Key entities

  • Lexicon

    Micro‑cap biotech reporting Q3 results.

Related articles

$LXRXMed

What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call

Lexicon Pharmaceuticals (LXRX) reported Q3 earnings, delaying ZYNQUISTA's diabetes application resubmission to Q1 2027 due to data preparation. The company presented preclinical obesity findings for pilavapadin and received a $10M milestone payment from Novo Nordisk. R&D expenses fell to $16.2M, while cash reserves stood at $183.2M.

$LXRXMed

Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data

Lexicon Pharmaceuticals (LXRX) reported Q3 2026 revenues of $11.3M, including a $10M milestone from Novo Nordisk. Key updates: Phase 3 Sonata HCM trial data expected Q1 2027, LX-9851 program advancing, and positive preclinical obesity data for pilavapidin. Net loss was $14.0M, or $0.03 per share, with $183.2M in cash. The company highlighted upcoming milestones, including the Sonata HCM data readout and Zynquista NDA resubmission in Q1 2027.

$LXRXMed

Lexicon (LXRX) Q3 2026 Earnings Call Transcript

Lexicon (LXRX) reported Q3 2026 progress, including completion of patient enrollment in the phase III SONATA-HCM study for HCM, with top-line results expected in Q1 2027. The company also made strides in resubmitting the NDA for ZYNQUISTA in type 1 diabetes, supported by new safety data from the STENO1 study, aiming for resubmission in Q1 2027.

$LXRXMed

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled…

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resu